-
Kitsap Respiratory Illness Report: March 19 – March 25
Advisory or Update, Communicable Disease and Immunization Update, Communicable Disease Data Report, COVID-19, Health Advisory, Infection Control, Influenza, Influenza Update, News and Alerts, News and Update, Provider Resources, Respiratory Illness Report, Respiratory Illness ReportClick here to access week 12 of the Kitsap Respiratory Illness Report. Summary: Local influenza activity is currently low, with 3 positive influenza tests in the past week (1,710 cumulative (15.5% of total tested) since 10/2/2022). RSV activity is currently low, with 0 positive RSV tests in the past week (491 since the start of the … Kitsap Respiratory Illness Report: March 19 – March 25
-
Providers advised to vaccinate all children against HPV beginning at age nine
Advisory or Update, HIV & STDs, Immunization, Immunizations, News and Update, Prevention, Provider Resources, SchoolsHPV vaccines are safe and highly effective in preventing infection with cancer-causing strains of HPV. The American Cancer Society, the American Academy of Pediatrics, and the CDC Advisory Committee on Immunization Practices (ACIP), and now the Washington Department of Health recommend starting this vaccination series at age 9. The HPV vaccine is one of the … Providers advised to vaccinate all children against HPV beginning at age nine
-
Kitsap Respiratory Illness Report: March 19 – March 25
Advisory or Update, Communicable Disease and Immunization Update, Communicable Disease Data Report, COVID-19, Health Advisory, Infection Control, Influenza, Influenza Update, News and Alerts, News and Update, Provider Resources, Respiratory Illness Report, Respiratory Illness ReportClick here to access week 12 of the Kitsap Respiratory Illness Report. Summary: Local influenza activity is currently low, with 3 positive influenza tests in the past week (1,710 cumulative (15.5% of total tested) since 10/2/2022). RSV activity is currently low, with 0 positive RSV tests in the past week (491 since the start of the … Kitsap Respiratory Illness Report: March 19 – March 25
-
Providers advised to vaccinate all children against HPV beginning at age nine
Advisory or Update, HIV & STDs, Immunization, Immunizations, News and Update, Prevention, Provider Resources, SchoolsHPV vaccines are safe and highly effective in preventing infection with cancer-causing strains of HPV. The American Cancer Society, the American Academy of Pediatrics, and the CDC Advisory Committee on Immunization Practices (ACIP), and now the Washington Department of Health recommend starting this vaccination series at age 9. The HPV vaccine is one of the … Providers advised to vaccinate all children against HPV beginning at age nine
-
03/07/22 Health Advisory: Update on Johnson & Johnson vaccine ordering and guidance for healthcare settings
Advisory or Update, COVID-19, Health Advisory, Immunizations, News and Alerts, Notifiable Conditions, Provider ResourcesRequested actions Be aware, on March 4, Washington State Department of Health (DOH) discontinued ordering Johnson & Johnson COVID-19 vaccine because inventory is very low at Centers for Disease Control and Prevention (CDC) in Washington Immunization Information System (IIS). We encourage providers to post and look for available doses on IIS vaccine advertisement page. Email … 03/07/22 Health Advisory: Update on Johnson & Johnson vaccine ordering and guidance for healthcare settings
-
Kitsap Respiratory Illness Report: February 20 – February 26, 2022
Click here to access the latest Kitsap Respiratory Illness Report: 2.20.22 – 2.26.22
-
Health Advisory: COVID-19 Updates for Providers
Advisory or Update, Communicable Disease and Immunization Update, COVID-19, Health Advisory, Health Alert, News and Alerts, News and Update, Notifiable Conditions, Novel Coronavirus, Provider Resources, SchoolsActions Requested Be aware, on Feb. 22, Centers for Disease Control and Prevention (CDC) revised its COVID-19 vaccine clinical considerations. An 8-week interval between first and second doses of mRNA COVID-19 vaccine (Moderna and Pfizer) may be optimal for males 12–39 years old to reduce risk of myocarditis and increase efficacy. CDC still recommends a … Health Advisory: COVID-19 Updates for Providers
-
02/25/22 Health Advisory: COVID-19 Updates for Providers
Requested actions Be aware, on Feb. 22, Centers for Disease Control and Prevention (CDC) revised its COVID-19 vaccine clinical considerations. An 8-week interval between first and second doses of mRNA COVID-19 vaccine (Moderna and Pfizer) may be optimal for males 12–39 years old to reduce risk of myocarditis and increase efficacy. CDC still recommends a … 02/25/22 Health Advisory: COVID-19 Updates for Providers
-
Kitsap Respiratory Illness Report: February 13 – February 19, 2022
Click here to access the latest Kitsap Respiratory Illness Report: 2.13.22 – 2.19-22
-
Kitsap Respiratory Illness Report February 6 – February 12, 2022
Click here to access the latest Kitsap Respiratory Illness Report: 2.6.22 – 2.12.22.
-
Health Advisory: COVID-19 Updates for Providers
Advisory or Update, Communicable Disease and Immunization Update, COVID-19, Emerging Diseases and Conditions, Health Alert, Immunization, Immunizations, News and Alerts, News and Update, Notifiable Conditions, Novel Coronavirus, Provider Resources, VaccineActions Requested Be aware, on February 11, the Centers for Disease Control and Prevention updated their guidance for COVID-19 vaccination to include: People who are moderately or severely immunocompromised should: Complete their primary series of 2 mRNA (Pfizer-BioNTech or Moderna) doses, a third dose at least 28 days after the initial two-dose series and an mRNA … Health Advisory: COVID-19 Updates for Providers
-
Kitsap Respiratory Illness Report January 30 – February 5, 2022
Click here to access the latest Kitsap Respiratory Illness Report: 1.30.22 – 2.5.22.
-
02/14/22 Health Advisory: CDC Updated Covid-19 Vaccination Guidelines; FDA Postponed its pediatric Covid-19 Vaccination Review
COVID-19 Updates for Providers Requested actions Be aware, on February 11, the Centers for Disease Control and Prevention updated their guidance for COVID-19 vaccination to include: For people who are moderately or severely immunocompromised: People who have completed a primary series of an mRNA vaccine (Pfizer-BioNTech or Moderna) are recommended to receive an mRNA booster … 02/14/22 Health Advisory: CDC Updated Covid-19 Vaccination Guidelines; FDA Postponed its pediatric Covid-19 Vaccination Review
-
Health Advisory: COVID-19 Updates
Advisory or Update, Communicable Disease and Immunization Update, COVID-19, Emerging Diseases and Conditions, Health Advisory, Health Alert, Immunizations, News and Alerts, Notifiable Conditions, Novel Coronavirus, Provider Resources, VaccineActions Requested Discuss a fourth dose of COVID-19 vaccine with immunocompromised patients. The Centers for Disease Control and Prevention (CDC) recommends people ages 5 and older who are moderately or severely immunocompromised should get an additional primary shot (third dose) of an mRNA vaccine 28 days after receiving their second dose. An additional primary shot … Health Advisory: COVID-19 Updates
-
Kitsap Respiratory Illness Report January 23 – January 29, 2022
Click here to access the latest Kitsap Respiratory Illness Report: 1.23.22 – 1.29.22.
-
02/01/22 Health Advisory: FDA Provides Full Approval For Spikevax
Advisory or Update, Communicable Disease and Immunization Update, COVID-19, Health Advisory, Notifiable Conditions, Provider Resources, UncategorizedCOVID-19 Updates for Providers Requested actions Be aware, U.S. Food and Drug Administration (FDA) granted full authorization to Moderna COVID-19 vaccine for people 18 years or older. Evidence shows the vaccine is safe and effective and manufactured with high quality. The vaccine will now be called Spikevax but has the same formulation as emergency use … 02/01/22 Health Advisory: FDA Provides Full Approval For Spikevax